Dr. Goy on Takeaways in Mantle Cell Lymphoma for the Future
In Partnership With:
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the takeaways for community oncologists in the field of mantle cell lymphoma (MCL).
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the takeaways for community oncologists in the field of mantle cell lymphoma (MCL).
It is important for researchers in the field to understand the significance of minimal residual disease and achieving a complete response (CR), Goy explains. There are tools available to make this happen, he adds. Also, researchers can limit therapy in patients who achieve a CR, and this will likely have a positive impact on cost control.
Combination regimens will also be a part of the future treatment landscape, says Goy. A potential option, he adds, includes chemotherapy as a maintenance therapy.
